News | June 23, 2014

Edwards Intuity Valve Data Demonstrate Improved Patient Benefits Over Standard Surgical Valves

June 23, 2014 — Edwards Lifesciences Corp. announced that three-year clinical outcomes of its Edwards Intuity valve platform demonstrated improved cardiac and valvular performance, as well as patient functional status.

These new data from the TRITON(1) trial were presented at the American Association for Thoracic Surgery’s (AATS) 94th annual meeting in Toronto by Thorsten Wahlers, M.D., Ph.D., Hospital and Health Center for Heart and Thoracic Surgery, University Clinic, Cologne, Germany.

The interim analysis of 287 patients who underwent aortic valve replacement with Intuity included 138 that received the next-generation Intuity Elite rapid-deployment valve. The platform combines the proven Carpentier-Edwards Perimount design with a balloon-expandable, cloth-covered frame, which enables the use of fewer sutures during valve replacement surgery.

"There is evidence from our experience that the expansion of the frame during valve implantation can potentially widen and reshape a narrowed left ventricular outflow tract, which directs blood flow into the aortic valve. This patient benefit was demonstrated in our study through clinically significant reductions in aortic valve mean pressure gradient and left ventricular size," said Wahlers. "This design element also helped clinicians better select a valve size most appropriate for the patient, which can be a challenge with conventioal valves, and enabled more efficient blood flow through the valve."

At three years, the study reported that rapid deployment aortic valve replacement using the Edwards Intuity valve platform in patients with aortic stenosis was associated with beneficial outcomes, including:

  • Statistically significantly hemodynamic performance improvement of the bioprosthetic valve, as indicated by a low aortic valve (AV) pressure gradient (mean 8.7 mmHg overall); and
  • Improved heart function, as demonstrated by a statistically significant reduction in left ventricular size over time (16 percent reduction in mean LV mass index).


"We are pleased that these data demonstrated important advantages that were meaningful for patients, which is significant given that the Edwards Intuity valve platform is built on the proven Carpentier-Edwards Perimount heart valve design and represents a new procedural approach to aortic valve surgery. We are continuing our launch of the Edwards Intuity Elite valve in Europe, to provide a new treatment option for surgeons that is built on a surgical valve platform they trust," said Donald E. Bobo Jr., Edwards' corporate vice president, heart valve therapy.

The Edwards Intuity Elite valve platform is currently being studied as part of the TRANSFORM trial, the first U.S. clinical trial of a rapid deployment aortic valve replacement. It is an investigational device and not yet available for sale or use in the United States.

For more information: www.edwards.com

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery| September 08, 2017
September 8, 2017 — ClearFlow Inc.
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Overlay Init